1-(2-甲基吡咯-1-基)乙酮 | 38207-11-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 1-(2-甲基吡咯-1-基)乙酮
• 英文名称: 1-Acetyl-2-methylpyrrol
• 英文别名: 1-(2-Methyl-1H-pyrrol-1-yl)ethan-1-one；1-(2-methylpyrrol-1-yl)ethanone
• CAS: 38207-11-3
• 化学式: C₇H₉NO
• 分子量: 123.155
• InChiKey: NSYCPFLGNNGDFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-(2,2-二甲基-1,3-恶唑-3-基)乙酮 在 对甲苯甲酸 作用下， 反应 1.0h， 以65%的产率得到1-(2-甲基吡咯-1-基)乙酮
  参考文献：
  名称：

  Weuthen, Manfred; Scharf, Hans-Dieter; Runsink, Jan, Chemische Berichte, 1987, vol. 120, p. 1023 - 1026

  摘要：

  DOI：

文献信息

• Thiadiazoline derivative
  申请人：Murakata Chikara

  公开号：US20070213380A1

  公开（公告）日：2007-09-13

  (wherein R 1 and R 4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R 5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R 2 represents —C(═W)R 6 or the like; R 3 represents a hydrogen atom, —C(═W A )R 6A , or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.

  本发明提供了一种以上述通式(I)所代表的噻二唑衍生物或其药学上可接受的盐为活性成分的抗肿瘤剂。其中R1和R4相同或不同，每个表示氢原子，取代或未取代的低级烷基，取代或未取代的低级炔基，取代或未取代的低级烯基或类似物；R5表示取代或未取代的杂环基，取代或未取代的芳基或类似物；R2表示-C(═W)R6或类似物；R3表示氢原子，-C(═WA)R6A或类似物。
• THIADIAZOLINE DERIVATIVE
  申请人：MURAKATA Chikara

  公开号：US20080207706A1

  公开（公告）日：2008-08-28

  (wherein R 1 and R 4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R 5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R 2 represents —C(═W)R 6 or the like; R 3 represents a hydrogen atom, —C(═W A )R 6A , or the like) Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.

  提供了一种抗肿瘤剂，其包括由上述一般式（I）表示的噻二唑啉衍生物或其药学上可接受的盐作为活性成分，其中R1和R4相同或不同，每个代表氢原子，取代或未取代的低碳基，取代或未取代的低炔基，取代或未取代的低烯基或类似物; R5代表取代或未取代的杂环基，取代或未取代的芳基或类似物; R2代表-C（═W）R6或类似物; R3代表氢原子，-C（═WA）R6A或类似物。
• Mitotic kinesin inhibitor
  申请人：Murakata Chikara

  公开号：US20070155804A1

  公开（公告）日：2007-07-05

  A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R 1 represents a hydrogen atom and the like, R 2 represents a hydrogen atom, —C(═W)R 6 (wherein W represents an oxygen atom or a sulfur atom, and R 6 represents substituted or unsubstituted lower alkyl and the like) and the like, R 3 represents —C(═Z)R 19 (wherein Z represents an oxygen atom or a sulfur atom, and R 19 represents substituted or unsubstituted lower alkyl and the like) and the like, R 4 represents substituted or unsubstituted lower alkyl and the like, and R 5 represents substituted or unsubstituted aryl and the like] and the like are provided.

  一种有丝分裂动力蛋白Eg5抑制剂，其包括由通式（I）表示的噻二唑衍生物或其药学上可接受的盐作为活性成分：[其中R1代表氢原子等，R2代表氢原子，-C（═W）R6（其中W代表氧原子或硫原子，R6代表取代或未取代的低级烷基等）等，R3代表-C（═Z）R19（其中Z代表氧原子或硫原子，R19代表取代或未取代的低级烷基等）等，R4代表取代或未取代的低级烷基等，R5代表取代或未取代的芳基等]等。
• Mitotic Kinesin Inhibitor
  申请人：KATO Kazuhiko

  公开号：US20110275827A1

  公开（公告）日：2011-11-10

  A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R 1 represents a hydrogen atom and the like, R 2 represents a hydrogen atom, —C(═W)R 6 (wherein W represents an oxygen atom or a sulfur atom, and R 6 represents substituted or unsubstituted lower alkyl and the like) and the like, R 3 represents —C(═Z)R 19 (wherein Z represents an oxygen atom or a sulfur atom, and R 19 represents substituted or unsubstituted lower alkyl and the like) and the like, R 4 represents substituted or unsubstituted lower alkyl and the like, and R 5 represents substituted or unsubstituted aryl and the like] and the like are provided.

  一种有丝分裂动力蛋白Eg5抑制剂，该抑制剂包括由通式（I）所表示的噻二唑衍生物或其药学上可接受的盐作为活性成分：[其中R1表示氢原子等，R2表示氢原子，-C（═W）R6（其中W表示氧原子或硫原子，R6表示取代或未取代的低碳基等）等，R3表示-C（═Z）R19（其中Z表示氧原子或硫原子，R19表示取代或未取代的低碳基等）等，R4表示取代或未取代的低碳基等，R5表示取代或未取代的芳基等]等。
• Catalyst and process for hydrogenating olefinically unsaturated compound
  申请人：JSR Corporation

  公开号：EP0974602A1

  公开（公告）日：2000-01-26

  A hydrogenation catalyst comprising (A) a transition metal compound in which a group having a heterocyclic skeleton is bonded to Ti, Zr or Hf through an oxygen atom or a nitrogen atom, a representative of which compound is bis(cyclopentadienyl)titanium bis(tetrahydrofurfuryloxy) and (B) an organic compound, halide or hydride of a metal of Groups I to III of the Periodic Table or comprising the constituent (A), the constituent (B) and (C) a polar, organic compound such as an alcohol, a carboxylic acid or the like. An olefinically unsaturated compound can be hydrogenated with a high efficiency by contacting the compound with hydrogen in the presence of the above catalyst in an inert, organic solvent. The above catalyst has a very high catalytic activity, is excellent in hydrogenation selectivity and thermal resistance, also excellent in storage stability and maintainability of catalytic activity and is hardly affected by the co-existing impurities.

  一种氢化催化剂，包括(A)一种过渡金属化合物，其中具有杂环骨架的基团通过氧原子或氮原子与 Ti、Zr 或 Hf 键合，该化合物的代表是双(环戊二烯基)双(四氢糠氧基)钛和(B)一种有机化合物、(C) 极性有机化合物，如醇、羧酸等。在惰性有机溶剂中，烯烃不饱和化合物在上述催化剂存在下与氢气接触，可以高效氢化。上述催化剂具有极高的催化活性，在氢化选择性和耐热性方面表现出色，在贮存稳定性和催化活性的可维持性方面也很出色，而且几乎不受共存杂质的影响。